AERIUS DUAL ACTION 24 HOUR TABLET (IMMEDIATE AND EXTENDED RELEASE)

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

Διαθέσιμο από:

BAYER INC

Φαρμακολογική κατηγορία (ATC):

R01BA52

INN (Διεθνής Όνομα):

PSEUDOEPHEDRINE, COMBINATIONS

Δοσολογία:

5MG; 240MG

Φαρμακοτεχνική μορφή:

TABLET (IMMEDIATE AND EXTENDED RELEASE)

Σύνθεση:

DESLORATADINE 5MG; PSEUDOEPHEDRINE SULFATE 240MG

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

100

Τρόπος διάθεσης:

OTC

Θεραπευτική περιοχή:

SECOND GENERATION ANTIHISTAMINES

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0252460002; AHFS:

Καθεστώς αδειοδότησης:

CANCELLED PRE MARKET

Ημερομηνία της άδειας:

2021-07-21

Αρχείο Π.Χ.Π.

_ _
_AERIUS_

_ DUAL ACTION 24 HOUR _
_Page 1 of 37_
PRODUCT MONOGRAPH
AERIUS
® DUAL ACTION 24 HOUR
DESLORATADINE 5 MG / PSEUDOEPHEDRINE SULFATE 240 MG
MODIFIED RELEASE TABLETS
HISTAMINE H1 RECEPTOR ANTAGONIST / SYMPATHOMIMETIC AMINE
Bayer Inc., Consumer Care
2920 Matheson Blvd. E
Mississauga, ON
L4W 5R6
Date of Revision:
July 10, 2015
Submission Control No: 184674
_ _
_AERIUS_

_ DUAL ACTION 24 HOUR _
_Page 2 of 37_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................16
SPECIAL HANDLING INSTRUCTIONS
.......................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................16
PART II: SCIENTIFIC INFORMATION
...............................................................................17
PHARMACEUTICAL INFORMATION
...............................................